§ IDAsia-Pacific
🇮🇩

Indonesia

Badan Pengawas Obat dan Makanan (National Agency of Drug and Food Control) (BPOM)

GEBy GlobalReg EditorialLast verified 4/25/2026
Updated 6 days agomedium confidence
Export PDF
Lead approval timeline
240–365 days
180–365 days · Reliance / Abridged Registration (SRA-approved or ASEAN reference)
Application fee
IDR 5.0M
IDR 5,000,000 · Per BPOM PNBP tariff schedule
English submissions
Accepted
Bahasa Indonesia, English
eCTD
CTD only
See dossier notes
Local representative
Required
RP also required
Reliance pathway
Available
9 reference agencies
Last verified 4/25/2026 · by GlobalReg Editorial
What this means: A snapshot of who regulates medicines in this country, what languages they accept, and which international standards they recognise.
Country brief
Indonesia

Indonesia regulates pharmaceutical products through Badan Pengawas Obat dan Makanan (BPOM) — the National Agency of Drug and Food Control. BPOM is an autonomous government agency reporting directly to the President. The legal framework rests on Law No. 17/2023 on Health, Government Regulation No. 28/2024, and BPOM Regulation No. 23/2025 (which superseded earlier registration rules and updated evaluation timelines, biological product classifications and labelling requirements). Marketing authorisation is evidenced by the Nomor Izin Edar (NIE). Indonesia is an ASEAN member that has implemented the ASEAN Common Technical Dossier (ACTD) and ACTR. BPOM operates New Drug, Generic, Biological and Variation pathways, with reliance on Stringent Regulatory Authorities (SRA) and ACTD-aligned ASEAN reference countries supporting abridged review for selected products. Indonesia is the world's largest Muslim-majority country and applies Halal certification to medicines under Law No. 33/2014 on Halal Product Assurance, with progressive enforcement deadlines administered by BPJPH (the Halal Product Assurance Agency). Public-sector reimbursement runs through JKN (Jaminan Kesehatan Nasional), the universal health insurance scheme administered by BPJS Kesehatan, with the Formularium Nasional (Fornas) as the gatekeeper for reimbursement.

Verified 4/25/2026 · GlobalReg Editorial
Regulatory authority
BPOM
Operating language
Bahasa Indonesia (English accepted for technical sections)
English submissions
Accepted
Submission languages
Bahasa Indonesia, English
CTD format
Accepted
eCTD format
Not accepted

About the authority

BPOM is Indonesia's national regulatory authority for medicines, biologicals, traditional medicines, health supplements, cosmetics and processed food. Within BPOM, the Deputi Bidang Pengawasan Obat (Deputy for Drug Control) administers product registration, GMP/GDP licensing, pharmacovigilance and post-market surveillance. Statutory marketing authorisation (Nomor Izin Edar, NIE) is issued by the Head of BPOM. BPOM has been a PIC/S member since 2012 and is an ICH Observer.

International affiliations

PIC/S (since 2012)WHOICH ObserverASEAN PPWG
Visit official website

Reliance & recognition

BPOM recognises Stringent Regulatory Authority (SRA) approvals and WHO Prequalification for abridged review and operates ASEAN harmonisation under ACTD/ACTR and the ASEAN Joint Assessment Coordinating Group (AJACG). A complete dossier and Bahasa Indonesia administrative documentation are still required.

FDA (US)EMAMHRA (UK)Health CanadaTGA (Australia)PMDA (Japan)SwissmedicWHO PrequalificationHSA (Singapore)

Compare Indonesia side-by-side

Benchmark timelines, fees and pathway requirements against another market.

Other Asia-Pacific markets

Same structure. Same source-citation standard.